Related Experiment Video
Updated: May 23, 2026
07:52
Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis
Published on: December 21, 2014
Targeting VEGF in lung cancer
1Stanford University, Stanford Cancer Center, CA, USA.
Expert Opinion on Therapeutic Targets
|March 24, 2012
Summary
Bevacizumab, an anti-VEGF antibody, is approved for lung cancer. Ongoing studies and biomarkers are crucial for understanding anti-angiogenic agents in non-small cell lung cancer (NSCLC) treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Vascular Endothelial Growth Factor (VEGF) drives tumor angiogenesis and is a key target in malignancies like non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To review the evidence supporting bevacizumab's approval for lung cancer.
- To examine clinical trial data for other anti-angiogenic agents in NSCLC treatment.
Main Methods:
- Review of data leading to bevacizumab approval.
- Analysis of Phase II and III trial results for anti-angiogenic agents in NSCLC.
- Inclusion of small-molecule tyrosine kinase inhibitors and vascular-disrupting agents (VDAs).
Main Results:
- Bevacizumab, a monoclonal antibody targeting VEGF, has gained approval for lung cancer treatment.
- Various anti-angiogenic agents, including TKIs and VDAs, are under investigation for NSCLC.
Conclusions:
- Further research and biomarker identification are essential to define the role of anti-angiogenic therapies in NSCLC treatment paradigms.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...